Hikma Pharmaceuticals Plc (HIK) Earns “Hold” Rating from Peel Hunt
Other analysts also recently issued research reports about the stock. Numis Securities Ltd reaffirmed an add rating and issued a GBX 1,560 ($20.52) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 17th. Morgan Stanley downgraded shares of Hikma Pharmaceuticals Plc to an equal weight rating and lowered their target price for the company from GBX 2,050 ($26.96) to GBX 1,600 ($21.04) in a report on Wednesday, August 2nd. Jefferies Group LLC lowered their target price on shares of Hikma Pharmaceuticals Plc from GBX 1,390 ($18.28) to GBX 1,045 ($13.74) and set a hold rating on the stock in a report on Monday, August 21st. Stifel Nicolaus downgraded shares of Hikma Pharmaceuticals Plc to a hold rating and lowered their target price for the company from GBX 2,300 ($30.25) to GBX 1,320 ($17.36) in a report on Tuesday, August 29th. Finally, J P Morgan Chase & Co lowered their target price on shares of Hikma Pharmaceuticals Plc from GBX 1,500 ($19.73) to GBX 1,250 ($16.44) and set a neutral rating on the stock in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. Hikma Pharmaceuticals Plc currently has a consensus rating of Hold and an average price target of GBX 1,321.91 ($17.39).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down GBX 17.04 ($0.22) during trading hours on Thursday, hitting GBX 981.46 ($12.91). 2,310,000 shares of the stock traded hands, compared to its average volume of 823,245. Hikma Pharmaceuticals Plc has a 1-year low of GBX 934 ($12.28) and a 1-year high of GBX 2,346 ($30.86).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.